BridgeMD
Personalized extended interval dosing of natalizumab in relapsing remitting multiple sclerosis (NEXT-MS)
EU CTIS ID: 2024-513105-31-00
What this study is testing
Our objective is to test feasibility and validate safety of personalized extended interval dosing of natalizumab starting from 6 weeks in a large real-life cohort across the Netherlands.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Diagnosis of relapsing remitting multiple sclerosis according to the 2017 criteria
- 6 or more consecutive natalizumab infusions
- 18 years or older
- Agreed to participate (written informed consent)
You likely can't join if
- High titer natalizumab (>100AU/ml) antibodies
- Contraindication for yearly magnetic resonance imaging (MRI) (ie, have pacemakers or other contraindicated implanted metal devices, or have claustrophobia that cannot be medically managed)
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.